Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. Specific clinical questions rise when patients, who are diagnosed with breast cancer, are at risk of carrying a mutation in BRCA1 and -2 gene due...
To the Editor: A family history of breast and/or ovarian cancer is associated with an increased chance of carrying a mutation in the BRCA1 or BRCA2 gene. Numerous societal guidelines define unaffected patient types appropriate for BRCA1/2 testing, including NCCN, ASCO, and USPSTF (1-3). ...
What happens if you test positive for BRCA gene? Prior to undergoing testing, it is essential that women consider the benefits and risks in light of the possible results. For example, if her test is positive (meaning she is affected by agenetic disorder) there are measures that can reduce ...
The Cost Effectiveness of Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes The discovery of BRCA1 and BRCA2 genes has led to the introduction of increasingly sophisticated genetic tests to measure the risk of hereditary breast cancer, among other things. The aim of this...
To evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and cascade testing in family members of BRCA mutation carriers. A cost-effectiveness analysis was conducted using a cohort Markov model from a health-payer perspective. The
The current method of testing for BRCA gene mutations,6,9-13 which is based on family history, often fails to identify many carriers. Family history–based testing will miss more than 50% of pathogenic variant carriers,14-16 which leaves a large number of women who are at risk for heredita...
ARTICLE Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue Wendy S. Rubinstein, MD, PhD1,2,3, Hongmei Jiang, PhD3,4, Lisa Dellefave, MS5, and Alfred W. Rademaker, PhD3,6 Purpose: About half of unaffected BRCA1/...
for Hereditary Breast and Ovarian Cancer Research September 25, 2024 Effects of Patient and Clinician Decision Support for BRCA1/2 Genetic Testing vs Standard Education Research July 18, 2022 Rare Pathogenic DNA Variants and Risk for Familial Clinical Disease Research April 29, 2020 Sign Up for ...
Overall, we compared 16 different strategies for breast and ovarian cancer prevention in women with BRCA-1/2 gene mutations. Strategies were based on current German recommendations [3, 6]. These recommendations state that women with BRCA-1/2 gene mutations should receive IS for breast cancer as...
Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation. JAMA Netw Open. 2019;2(8):e198420. doi:10.1001/jamanetworkopen.2019.8420 ArticlePubMedGoogle Scholar Gene-Specific Guidelines for Risk Management of Gynecological C...